Concepedia

Klas Bergenheim

KB

24

Publications

924

Citations

18

H-Index

2005

Active since

Affiliations

AstraZeneca (Sweden)(Current)

Health Economics and Outcomes Research (United Kingdom)

Swansea University

AstraZeneca (United Kingdom)

Cardiff University

Klas Bergenheim is an author at AstraZeneca (Sweden) specializing in diabetes, health economics, and medicine.

ORCID

Top concepts

Publications per year

2005–2022

24

Publications

24

Cost-Effectiveness of Dapagliflozin as a Treatment for Heart Failure with Reduced Ejection Fraction: A Multinational Health-Economic Analysis of DAPA-HF

Phil McEwan, Oliver Darlington, John J.V. McMurray et al. · European Journal of Heart Failure · 2020 · 144 citations · Full text

Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation cost-utility model (DiabForecaster)

Phil McEwan, John R. Peters, Klas Bergenheim et al. · Current Medical Research and Opinion · 2005 · 85 citations

Cost-Effectiveness of Dapagliflozin as a Treatment for Chronic Kidney Disease

Phil McEwan, Oliver Darlington, Ryan Miller et al. · Clinical Journal of the American Society of Nephrology · 2022 · 58 citations · Full text

A population model evaluating the costs and benefits associated with different oral treatment strategies in people with type 2 diabetes

P McEwan, Marc Evans, Klas Bergenheim · Diabetes Obesity and Metabolism · 2010 · 51 citations

Validation of the UKPDS 82 risk equations within the Cardiff Diabetes Model

Philip McEwan, Thomas Ward, Hayley Bennett et al. · Cost Effectiveness and Resource Allocation · 2015 · 46 citations · Full text

Rows per page

1–5 of 24